Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06946927RecruitingPhase 1
Study of JMKX001899 with other drugs for advanced KRAS G12C lung cancer
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT06948981RecruitingPhase 1/Phase 2
GT719 Injection for Relapsed CD19+ B-cell Cancers
This trial tests a new injection called GT719 for adults with B-cell cancers that have come back or not responded to treatment. The cancer cells must have a marker called CD19. The study aims to see if the treatment is safe and works.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06938867RecruitingPhase 1/Phase 2
Study of SNIPR001 for stem cell transplant patients
This trial tests an oral treatment called SNIPR001 that targets a type of E. coli bacteria resistant to common antibiotics. It may help prevent infections during stem cell transplant recovery.
Duarte, CaliforniaAges 18 years+ - NCT06940180RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for sinus cancer
This trial tests a combination of an immunotherapy drug (toripalimab) plus chemotherapy before surgery for sinus cancer that has not spread. The goal is to see if this treatment shrinks the tumor so surgery can be more effective.
Boston, MassachusettsAges 18 years+ - NCT06937866RecruitingPhase 1/Phase 2
Zanzalintinib and etoposide after high-dose chemo for germ cell tumors
This trial tests a maintenance therapy combining zanzalintinib and etoposide after you've completed high-dose chemotherapy and a stem cell transplant for germ cell cancer. The goal is to see if this drug combination helps prevent the cancer from coming back.
Indianapolis, IndianaAges 18 years+ - NCT06935344Recruiting
Can genes predict ovarian cancer risk?
This study looks at whether a score based on your genes can predict the risk of epithelial ovarian cancer. It compares women newly diagnosed with this cancer to women who have never had it.
Roma, ItaliaAges 18 years+ - NCT06935188RecruitingPhase 2
Dalpiciclib plus cetuximab for certain head and neck cancers
This trial tests a new combination of two drugs (dalpiciclib and cetuximab) versus cetuximab alone for people with head and neck cancer that is HPV-negative, has not responded to prior immunotherapy, and is not curable with surgery. The goal is to see if the combination works better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06550427Recruiting
Lymphoma treatment response monitoring with genetic testing
This trial is testing a new way to monitor how well your lymphoma treatment is working. It uses a blood test to look for genetic changes in cancer cells, which may help doctors make better treatment decisions.
TaipeiAges 18 years+ - NCT06775678RecruitingPhase 2
Spatial fragmentation plus low-dose radiation for resistant lung cancer
This study tests whether combining a special type of radiation (spatial fragmentation) with low-dose radiation can help people whose lung cancer stopped responding to immunotherapy and chemotherapy. If you are eligible, you may receive a new treatment approach to try to shrink the tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06785324Recruiting
Nutrition and exercise for adults with ALL in the hospital
This trial tests whether adding a structured diet and exercise program during your hospital stay for newly diagnosed ALL can help your recovery. You must have a specific type of ALL and be receiving a certain chemotherapy regimen.
Chicago, IllinoisAges 18–50 - NCT06923618Recruiting
Lung Cancer and Aging in Older Adults
This trial looks at aging-related changes in older adults (70+) with early-stage lung cancer who are planning to have surgery. The goal is to better understand how these changes might affect recovery and outcomes, which could help improve care for future patients.
Créteil, Île-de-France RegionAges 70 years+ - NCT06930976Recruiting
Tracing sugar use in immune cells
This study uses a special sugar (glucose) to see how your immune cells use energy. You drink a labeled sugar, then give blood samples so researchers can track it.
Nashville, TennesseeAges 18 years+ - NCT06926595RecruitingPhase 2
Stem cell transplant with low-dose chemo for graft-versus-host disease prevention
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
Hershey, PennsylvaniaAges 18 years+ - NCT06922890RecruitingPhase 1/Phase 2
Gene therapy for chronic spinal cord injury (AIS-A/B)
This trial tests a new gene therapy called STUP-001 that aims to repair spinal cord damage directly. It is for people who have had a traumatic spinal cord injury with complete or near-complete paralysis (AIS-A or B) for at least 6 months.
SeoulAges 19–60 - NCT06931652RecruitingPhase 2
Epcoritamab with lenalidomide and rituximab for CNS lymphoma
This trial tests a new combination of drugs—epcoritamab, lenalidomide, and rituximab—for people with primary central nervous system lymphoma (PCNSL) that has come back or not responded to treatment. The goal is to see if this three-drug therapy can help control the cancer.
BordeauxAges 18 years+ - NCT06925685Enrolling by invitation
Long-term follow-up after CAR T-cell therapy
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
Buffalo, New YorkAges Any age - NCT06930794RecruitingPhase 3
Study of Vebreltinib Plus Chemo for MET-Positive Lung Cancer
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06276283RecruitingPhase 2
DZD9008 plus bevacizumab for EGFR-mutated advanced lung cancer
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06918002RecruitingPhase 3
Comparing elranatamab with standard care for newly diagnosed multiple myeloma
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
BrusselsAges 18–69 - NCT06912347Enrolling by invitation
Herbal therapy to prevent infection after stem cell transplant
This trial tests whether a special herbal treatment applied to the skin can help prevent infections around the bottom that are caused by diarrhea after a stem cell transplant. It may be an option for people who are getting a transplant for the first time.
Shanghai, Shanghai MunicipalityAges 14–70 - NCT06915454Recruiting
Better imaging during cancer surgery
This trial tests a high-resolution PET-CT scan done during surgery to help surgeons see exactly where the cancer ends. It may help make sure all cancer is removed while saving healthy tissue.
Nashville, TennesseeAges 18 years+ - NCT06918834RecruitingPhase 2
Immediate vs bridging transplant for high-risk MDS
This trial compares getting a stem cell transplant right away versus getting other treatments first before transplant for people with high-risk myelodysplastic syndrome (MDS), a bone marrow disorder. It aims to see which approach leads to better outcomes.
Beijin, Beijing MunicipalityAges 18 years+ - NCT06916767RecruitingPhase 1
Study of BAFF CAR-T cells for CLL or SLL
This trial tests a new type of immune cell therapy (BAFF CAR-T cells) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded after at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if these engineered cells can fight the cancer.
Cleveland, OhioAges 18 years+ - NCT06919874Recruiting
Yoga app for lung or esophageal cancer patients and their caregivers
This trial tests a mobile app that guides patients with lung or esophageal cancer and their family caregivers through yoga exercises. It aims to improve well-being during radiation treatment.
Houston, TexasAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.